OTC Decisions In February: 2 Switches, Label Changes For Excedrin, FeverAll, Naproxen From Biopharma

Editor's note: With information on February decisions, HBW Insight continues our ongoing feature to provide information on decisions by the US Food and Drug Administration on new drug applications, including ANDAs, for nonprescription drugs and on supplemental NDAs about label and package changes for approved OTC products.

The Food and Drug Administration on one day in February approved initial OTC sales in the US of not one but two ingredients – diclofenac sodium topical gel and olopatadine...